The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

被引：0
|
作者：
Rachna T Shroff
Mark Yarchoan
Ashley O'Connor
Denise Gallagher
Marianna L Zahurak
Gary Rosner
Chimela Ohaji
Susan Sartorius-Mergenthaler
Vivek Subbiah
Ralph Zinner
Nilofer S Azad
机构：
[1] The University of Texas MD Anderson Cancer Center,
[2] Gastrointestinal Oncology,undefined
[3] Sidney Kimmel Comprehensive Cancer Center,undefined
[4] Johns Hopkins University,undefined
来源：
British Journal of Cancer | 2017年 / 116卷
关键词：
cholangiocarcinoma; trametinib; MEK; pazopanib; VEGF; RAS; angiogenesis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1402 / 1407
页数：5
相关论文
共 50 条
  • [21] Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
    Tolcher, Anthony W.
    Patnaik, Amita
    Papadopoulos, Kyriakos P.
    Rasco, Drew W.
    Becerra, Carlos R.
    Allred, Alicia J.
    Orford, Keith
    Aktan, Gursel
    Ferron-Brady, Geraldine
    Ibrahim, Nageatte
    Gauvin, Jennifer
    Motwani, Monica
    Cornfeld, Mark
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (01) : 183 - 189
  • [22] MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas
    Umapathy, Ganesh
    Guan, Jikui
    Gustafsson, Dan E.
    Javanmardi, Niloufar
    Cervantes-Madrid, Diana
    Djos, Anna
    Martinsson, Tommy
    Palmer, Ruth H.
    Hallberg, Bengt
    SCIENCE SIGNALING, 2017, 10 (507)
  • [23] Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
    Piha-Paul, Sarina A.
    Wheler, Jennifer J.
    Fu, Siqing
    Levenback, Charles
    Lu, Karen
    Falchook, Gerald S.
    Naing, Aung
    Hong, David S.
    Tsimberidou, Apostolia M.
    Kurzrock, Razelle
    ONCOTARGET, 2014, 5 (07) : 1846 - 1855
  • [24] A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
    Piha-Paul, Sarina A.
    Dumbrava, Ecaterina E.
    Nair, Binoj C.
    Xiong, Wendy
    Xu, Li
    Mostorino, Rosa
    Subbiah, Vivek
    Tannir, Nizar
    Fu, Siqing
    Naing, Aung
    Janku, Filip
    Karp, Daniel D.
    Patel, Shreyaskumar
    Daw, Najat C.
    Hong, David
    Meric-Bernstam, Funda
    Zinner, Ralph
    ONCOTARGETS AND THERAPY, 2021, 14 : 3037 - 3049
  • [25] A Phase Ib Study of the VEGF Receptor Tyrosine Kinase Inhibitor Tivozanib and Modified FOLFOX-6 in Patients With Advanced Gastrointestinal Malignancies
    Oldenhuis, Corina N.
    Loos, Walter J.
    Esteves, Brooke
    van Doorn, Leni
    Cotreau, Monette M.
    Strahs, Andrew L.
    den Hollander, Martha W.
    Gietema, Jourik A.
    de Vries, Elisabeth G. E.
    Eskens, Ferry A. L. M.
    CLINICAL COLORECTAL CANCER, 2015, 14 (01) : 18 - 24
  • [26] Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer
    Roviello, Giandomenico
    Ravelli, Andrea
    Polom, Karol
    Petrioli, Roberto
    Marano, Luigi
    Marrelli, Daniele
    Roviello, Franco
    Generali, Daniele
    CANCER LETTERS, 2016, 372 (02) : 187 - 191
  • [27] Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors
    Shah, Hiral A.
    Fischer, James H.
    Venepalli, Neeta K.
    Danciu, Oana C.
    Christian, Sonia
    Russell, Meredith J.
    Liu, Li C.
    Zacny, James P.
    Dudek, Arkadiusz Z.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (05): : 413 - 420
  • [28] Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers
    Ho, May Y. K.
    Morris, Michael J.
    Pirhalla, Jill L.
    Bauman, John W.
    Pendry, Carolyn B.
    Orford, Keith W.
    Morrison, Royce A.
    Cox, Donna S.
    XENOBIOTICA, 2014, 44 (04) : 352 - 368
  • [29] A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer
    Pili, Roberto
    Qin, Rui
    Flynn, P. J.
    Picus, Joel
    Millward, Michael
    Ho, Wing Ming
    Pitot, Henry
    Tan, Winston
    Miles, Kiersten M.
    Erlichman, Charles
    Vaishampayan, Ulka
    CLINICAL GENITOURINARY CANCER, 2013, 11 (04) : 477 - 483
  • [30] A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
    Chenard-Poirier, Maxime
    Hansen, Aaron R.
    Gutierrez, Martin E.
    Rasco, Drew
    Xing, Yan
    Chen, Lin-Chi
    Zhou, Heng
    Webber, Andrea L.
    Freshwater, Tomoko
    Sharma, Manish R.
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (03) : 241 - 251
12345